二聚体并非永远存在：CD80 与 PD-L1 分手。
Dimers Aren't Forever: CD80 Breaks up with PD-L1.
机构信息
UCL Institute of Immunity and Transplantation, Royal Free Hospital, London NW3 2PF, UK.
出版信息
Immunity. 2019 Dec 17;51(6):972-974. doi: 10.1016/j.immuni.2019.11.011.
PMID:31951541
Abstract
Targeting the CTLA-4 and PD-1 "checkpoints" is an effective treatment for a number of cancers. In this issue of Immunity, Hui et al. reveal that interaction between a CTLA-4 ligand, CD80, and its counterpart in the PD-1 pathway, PD-L1, affects both PD-1 and CTLA-4 function, raising new questions about the biological effects of using checkpoint inhibitors alone and in combination.
摘要
针对 CTLA-4 和 PD-1“检查点”的靶向治疗是治疗多种癌症的有效方法。在本期《免疫》中，Hui 等人揭示了 CTLA-4 配体 CD80 与其 PD-1 通路对应物 PD-L1 之间的相互作用会影响 PD-1 和 CTLA-4 的功能，这就提出了关于单独和联合使用检查点抑制剂的生物学效应的新问题。
Zotero 插件